Surmodics (SRDX) 10-Q 29 Jul 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2016	Jul. 22, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	SRDX
Entity Registrant Name	SURMODICS INC
Entity Central Index Key	924,717
Current Fiscal Year End Date	--09-30
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		13,045,714

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2016	Sep. 30, 2015
Current Assets:
Cash and cash equivalents	$ 34,656	$ 55,588
Available-for-sale securities	9,523
Accounts receivable, net of allowance for doubtful accounts of $19 and $10 as of June 30, 2016 and September 30, 2015, respectively	5,859	7,478
Inventories	3,345	2,979
Deferred tax assets		546
Prepaids and other	686	1,198
Total Current Assets	54,069	67,789
Property and equipment, net	17,183	12,968
Deferred tax assets	5,555	6,704
Intangible assets, net	22,889	2,760
Goodwill	26,544	8,010
Other assets, net	674	479
Total Assets	126,914	98,710
Current Liabilities:
Accounts payable	1,547	781
Accrued liabilities:
Compensation	3,020	2,772
Due to customers	1,741	63
Accrued other	1,493	731
Business combination consideration payable		305
Deferred revenue	268	48
Total Current Liabilities	8,069	4,700
Contingent consideration	13,950
Deferred revenue, less current portion	192	217
Other long-term liabilities	1,897	1,920
Total Liabilities	24,108	6,837
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Series A Preferred stock- $.05 par value, 450,000 shares authorized; no shares issued and outstanding
Common stock- $.05 par value, 45,000,000 shares authorized; 13,040,978 and 12,945,157 shares issued and outstanding, respectively	652	647
Additional paid-in capital	5,764	3,060
Accumulated other comprehensive income	888	5
Retained earnings	95,502	88,161
Total Stockholders’ Equity	102,806	91,873
Total Liabilities and Stockholders’ Equity	$ 126,914	$ 98,710

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2016	Sep. 30, 2015
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 19	$ 10
Series A Preferred stock, par value	$ 0.05	$ 0.05
Series A Preferred stock, shares authorized	450,000	450,000
Series A Preferred stock, shares issued	0	0
Series A Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	13,040,978	12,945,157
Common stock, shares outstanding	13,040,978	12,945,157

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue:
Royalties and license fees	$ 10,556	$ 7,908	$ 25,207	$ 22,566
Product sales	7,512	6,583	22,866	18,082
Research, development and other	1,904	1,423	5,139	3,887
Total revenue	19,972	15,914	53,212	44,535
Operating costs and expenses:
Product costs	2,777	2,174	8,069	6,031
Research and development	4,693	3,860	13,195	11,839
Selling, general and administrative	4,483	3,872	12,984	11,387
Acquisition transaction, integration and other costs	61		3,192
Acquisition related intangible asset amortization	806	151	1,940	454
Contingent consideration accretion expense	555		1,056
Total operating costs and expenses	13,375	10,057	40,436	29,711
Operating income	6,597	5,857	12,776	14,824
Other income (loss):
Investment income, net	19	36	37	149
Gain on strategic investments	16		377
Foreign exchange gain (loss)	234		(336)
Other (loss) income, net	(6)	(40)	(6)	496
Other income (loss) , net	263	(4)	72	645
Income before income taxes	6,860	5,853	12,848	15,469
Income tax provision	(2,857)	(1,929)	(5,507)	(4,879)
Net income	$ 4,003	$ 3,924	$ 7,341	$ 10,590
Basic net income per share	$ 0.31	$ 0.30	$ 0.57	$ 0.81
Diluted net income per share	$ 0.30	$ 0.30	$ 0.56	$ 0.79
Weighted average number of shares outstanding:
Basic	12,995	13,002	12,969	13,057
Diluted	13,284	13,279	13,203	13,324

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 4,003	$ 3,924	$ 7,341	$ 10,590
Other comprehensive income (loss), net of tax:
Unrealized holding losses on available-for-sale securities arising during the period	(34)	(59)	(36)	(1,216)
Reclassification adjustment for realized gains included in net income		26		(315)
Foreign currency translation adjustments	(809)		919
Other comprehensive (loss) income	(843)	(33)	883	(1,531)
Comprehensive income	$ 3,160	$ 3,891	$ 8,224	$ 9,059

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating Activities:
Net income	$ 7,341	$ 10,590
Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:
Depreciation and amortization	3,703	2,083
Stock-based compensation	2,729	1,841
Contingent consideration expense and unrealized foreign exchange loss	1,369
Deferred taxes	(114)	450
Gain on sales of available-for-sale securities and strategic investments	(377)	(496)
Excess tax benefit from stock-based compensation plans	(67)	(436)
Other	(15)	(42)
Change in operating assets and liabilities, net of acquisitions:
Accounts receivable	1,999	(1,244)
Inventories	(112)	(647)
Prepaids and other	45	66
Accounts payable and accrued liabilities	746	132
Income taxes	1,253	(221)
Net cash provided by operating activities from continuing operations	18,500	12,076
Investing Activities:
Purchases of property and equipment	(4,869)	(396)
Cash proceeds from sales of property and equipment	15	42
Payments for acquisitions, net of cash acquired	(25,054)
Purchases of available-for-sale securities	(9,562)	(3,377)
Sales and maturities of available-for-sale securities		22,199
Cash received from sale of strategic investments	377	21
Cash transferred to discontinued operations		(45)
Net cash (used in) provided by investing activities from continuing operations	(39,093)	18,444
Financing Activities:
Excess tax benefit from stock-based compensation plans	67	436
Issuance of common stock	284	451
Repurchase of common stock		(20,000)
Purchase of common stock to pay employee taxes	(371)	(810)
Payment of contingent consideration	(305)
Net cash used in financing activities from continuing operations	(325)	(19,923)
Net cash (used in) provided by continuing operations	(20,918)	10,597
Discontinued Operations:
Net cash used in operating activities		(45)
Net cash provided by financing activities		45
Effect of exchange rate changes on cash	(14)
Net change in cash and cash equivalents	(20,932)	10,597
Cash and Cash Equivalents:
Beginning of period	55,588	43,511
End of period	34,656	54,108
Supplemental Information:
Cash paid for income taxes	4,313	4,651
Noncash transactions from investing and financing activities:
Acquisition of property and equipment on account	133	113
Contingent consideration and debt assumed in acquisitions	13,597
Issuance of performance shares, restricted and deferred stock units	$ 1,390	$ 2,250

Basis of Presentation

Basis of Presentation	9 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.”) (“GAAP”) and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, needed to fairly present the financial results of Surmodics, Inc. and subsidiaries (“Surmodics” or the “Company”) for the periods presented. The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of the assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. The results of operations for the three and nine months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the entire 2016 fiscal year. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2015, and footnotes thereto included in the Company’s Form 10-K as filed with the SEC on December 4, 2015, and as amended on May 10, 2016. On July 11, 2016, we amended our articles of incorporation to change our name from SurModics, Inc., to Surmodics, Inc., which change became effective immediately. The name change was effected by our board of directors. During the nine months ended June 30, 2016 the Company recorded an out-of-period adjustment of $1.1 million in the second quarter of fiscal 2016 to correct an estimated cumulative overstatement of royalty revenue with a customer, of which $1.0 million related to years prior to fiscal 2016. The overstatement was evaluated and concluded to not be material to fiscal 2016, the nine- months ended June 30, 2016, or any prior periods. During the quarter ended June 30, 2016, the Company entered into a settlement agreement with this customer and agreed to pay the customer a total of $1.4 million to settle this matter. The additional obligation amount settled was considered to be a change in estimate and was recorded as a reduction of royalty revenue during the quarter ended June 30, 2016. The total settlement amount of $1.4 million was included in the Due to Customer liability on the consolidated balance sheet at June 30, 2016 and was paid in July 2016. On April 29, 2016, a customer reported $2.9 million, of royalties was owed to the Company for the period from fiscal 2009 through 2016. Payment of this amount was received and royalty revenue was recognized in the third quarter of fiscal 2016, when collectability was reasonably assured and completion of the earnings process occurred, consistent with the Company’s revenue recognition policy.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements	2. New Accounting Pronouncements Accounting Standards to be Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-09, Revenue from Contracts with Customers (ASC Topic 606) require entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting standard will be effective for the Company beginning in the first quarter of fiscal year 2019 (October 1, 2018) using one of two prescribed retrospective methods. The Company is currently evaluating the impact that the adoption of this standard will have on the Company’s results of operations, cash flows and financial position. In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (ASC Topic 842) In March 2016, the FASB issued ASU No 2016-09, Compensation – Stock Compensation (ASC Topic 718): Improvements to Employee Share-Based Payment Accounting In June 2016, the FASB issued ASU No 2016-13, Financial Instruments – Credit Losses (ASU Topic 326), Measurement of Credit Losses on Financial Statements Accounting Standards Adopted In September 2015, the FASB issued ASU 2015-16, Business Combinations (ASC Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s consolidated financial statements.

Business Combinations

Business Combinations	9 Months Ended
	Jun. 30, 2016
Business Combinations [Abstract]
Business Combinations	3. Business Combinations For all business combinations, the Company records all assets and liabilities of the acquired business, including goodwill and other identified intangible assets, generally at their fair values starting in the period when the acquisition is completed. Contingent consideration, if any, is recognized at its fair value on the acquisition date and changes in fair value are recognized in earnings until settlement. Acquisition-related transaction costs are expensed as incurred. Creagh Medical Ltd. On November 20, 2015, the Company acquired 100% of the outstanding common shares and voting shares of Creagh Medical Ltd. (“Creagh Medical”) located in Ballinasloe, Ireland. The results of Creagh Medical’s operations have been included in the Company’s condensed consolidated financial statements as of the Creagh Medical acquisition date. The acquisition was financed with cash on hand. The Company acquired Creagh Medical for up to €30 million (approximately $32 million as of the acquisition date), including an upfront payment of €18 million (approximately $19.3 million as of the acquisition date), and up to €12 million (approximately $12.8 million as of the acquisition date) based on achievement of revenue and value-creating operational milestones through September 30, 2018. The payment of the milestones if met will occur in the quarter ending December 31, 2018. As of June 30, 2016, the Company had paid $18.4 million in cash for this acquisition, in addition to $0.8 million to an escrow account to fund the repurchase of certain Creagh Medical debt classified securities during fiscal 2016. As these securities were not initially legally defeased by the establishment of the escrow fund, the Company recorded a corresponding restricted cash and business combination consideration payable in prior periods. These securities were repaid in the third quarter of fiscal 2016. The Company also assumed $0.8 million of debt that was repaid in the second quarter of fiscal 2016. Total transaction, integration and other costs associated with the Creagh Medical acquisition aggregated less than $0.1 million and $2.7 million for the three and nine months ended June 30, 2016, respectively. Creagh Medical is included in the Company’s Medical Device reporting segment. Creagh Medical designs and manufactures high-quality percutaneous transluminal angioplasty (“PTA”) balloon catheters. Since 2006, Creagh Medical has grown its technical and product capability with PTA products approved throughout the world, including Europe, the United States, and Japan. With these resources, the Company is uniquely positioned to offer a total solutions approach from product design and development, through in-house extrusion, balloon forming, top-assembly, packaging and regulatory capabilities to approved products for exclusive distribution. The acquisition is a major step forward in the Company’s strategy to transform its Medical Device segment from being a provider of coatings technologies to offering whole-product solutions to medical device customers in the large and growing global interventional vascular market. The purchase price of Creagh Medical consisted of the following: (Dollars in thousands) Cash paid $ 18,417 Debt assumed 793 Contingent consideration 9,064 Total purchase price 28,274 Less cash and cash equivalents acquired (251 ) Total purchase price, net of cash acquired $ 28,023 The following table summarizes the preliminary allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition: Fair Value (Dollars Estimated (In Current assets $ 708 N/A Property and equipment 634 1.0-10.0 Trade name 75 N/A Developed technology 1,787 7.0 In-process research and development 942 N/A Customer relationships 11,119 7.0-10.0 Other noncurrent assets 81 N/A Current liabilities (923 ) N/A Deferred tax liabilities (9 ) N/A Net assets acquired 14,414 Goodwill 13,609 N/A Total purchase price, net of cash acquired $ 28,023 The Creagh Medical goodwill is a result of acquiring and retaining the Creagh Medical existing workforce and expected synergies from integrating their business into Surmodics. The goodwill will not be deductible for tax purposes. Purchase accounting is considered preliminary, subject to revision, mainly with respect to working capital, income taxes and goodwill, as final information was not available as of June 30, 2016. As a result of the Creagh Medical acquisition, the Company has adopted a foreign currency translation policy. Assets and liabilities of non-U.S. dollar functional currency subsidiaries are translated into U.S. dollars at the period-end exchange rates, and revenues and expenses are translated at the average exchange rate for the period. The net effect of these translation adjustments in the condensed consolidated financial statements are recorded as a foreign currency translation adjustment, as a component of accumulated other comprehensive income. Foreign currency transaction gains and losses are included in other, income (loss) net in our Condensed Consolidated Statements of Income. NorMedix, Inc. On January 8, 2016, the Company acquired 100% of the shares of NorMedix, Inc. (“NorMedix”), a privately owned design and development company focused on ultra thin-walled, minimally invasive catheter technologies based in Plymouth, Minnesota. The acquisition was financed with cash on hand. The Company acquired NorMedix for $14.0 million, including an upfront payment of $6.9 million, and up to $7.0 million based on achievement of revenue and value-creating operational milestones through September 30, 2019. Contingent consideration associated with the NorMedix transaction is payable as earned. This acquisition strengthens the Company’s vascular device expertise and Research and Development (“R&D) capabilities. This acquisition positions the Company to make significant progress on its strategy to offer whole-product solutions to medical device customers, while continuing its commitment to consistently deliver innovation in coating technologies and in vitro diagnostics. Total transaction, integration and other costs associated with the NorMedix acquisition aggregated $0.0 million and $0.3 million for the three and nine months, respectively, ended June 30, 2016. NorMedix is included in the Company’s Medical Device reporting segment. The purchase price of NorMedix consisted of the following: (Dollars in thousands) Cash paid $ 6,905 Contingent consideration 3,740 Total purchase price 10,645 Less cash and cash equivalents acquired (17 ) Total purchase price, net of cash acquired $ 10,628 The following table summarizes the allocation of the preliminary purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition: Fair Value (Dollars Estimated Useful Life (In years) Net current assets $ 196 N/A Property and equipment 76 N/A Developed technology 6,850 10.0-14.0 Customer relationships 900 4.0 Deferred tax asset 812 N/A Other noncurrent asset 12 N/A Deferred tax liabilities (2,597 ) N/A Net assets acquired 6,249 Goodwill 4,379 N/A Total purchase price, net of cash acquired $ 10,628 The NorMedix goodwill is a result of acquiring and retaining the NorMedix existing workforce and expected synergies from integrating their business into Surmodics. The goodwill will not be deductible for tax purposes. Purchase accounting is considered preliminary, subject to revision, mainly with respect to working capital, income taxes and goodwill, as final information was not available as of June 30, 2016. These strategic acquisitions combine the best-in-class capabilities of NorMedix’s catheter-based technologies, Creagh Medical’s PTA balloon platform capabilities, and Surmodics’ innovative coating and drug delivery technologies to develop highly differentiated delivery and therapeutic intravascular solutions. The result is an organization with unique device design and development expertise, rich technology content, manufacturing capabilities, and a state-of-the-art facility equipped for medical device R&D and manufacturing. Pro Forma Results The following unaudited pro forma financial information presents the combined results of operation of the Company as if the acquisitions of Creagh Medical and NorMedix had occurred as of October 1, 2014. The Company has realized $2.8 million of revenue and a net loss of $2.3 million from the Creagh Medical and NorMedix operations since their acquisitions. The fiscal 2016 nine month pro forma financial information includes adjustments for additional amortization expense on identifiable intangible assets of $0.4 million and contingent consideration accretion expense of $0.3 million, eliminating non-recurring transactional professional fees of $3.0 million, and tax effect impact of $0.1 million. The fiscal 2015 three and nine month pro forma financial information includes adjustments for additional amortization expense on identifiable intangible assets of $0.6 million and $1.9 million, contingent consideration accretion expense of $0.1 million and $0.9 million and tax effect impact of $0.1 million and $0.4 million, respectively. The tax impact of the adjustments in all periods reflects no tax benefit from contingent consideration accretion as well as a significant portion of our transaction related costs in fiscal 2016 as they are not deductible for tax purposes. Further, Creagh Medical amortization expense does not reflect an Irish tax benefit as we acquired a net operating loss carryforward as of the acquisition date that was offset in the aggregate by deferred tax liabilities and valuation allowance. Therefore, the amortization of Creagh Medical intangible assets results in a decrease in deferred tax liabilities with a corresponding increase to a deferred tax valuation allowance. NorMedix amortization expense reflects a tax benefit based on our incremental U.S. tax rate. The unaudited pro forma financial information is not necessarily indicative of what the Company’s consolidated results of operations actually would have been had the acquisition occurred at the beginning of each year. Additionally, the unaudited pro forma financial information does not attempt to project the future results of operations of the combined company. Three Months Ended Nine Months Ended June 30, June 30, 2015 2016 2015 (In thousands, except per share data) (Unaudited) (Unaudited) Revenue $ 16,858 $ 54,262 $ 46,922 Net income $ 1,232 $ 6,857 $ 2,347 Per share amounts: Basic net income per share $ 0.09 $ 0.53 $ 0.18 Diluted net income per share $ 0.09 $ 0.52 $ 0.18

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The accounting guidance on fair value measurements defines fair value, establishes a framework for measuring fair value under GAAP, and expands disclosures about fair value measurements. The guidance is applicable for all financial assets and financial liabilities and for all nonfinancial assets and nonfinancial liabilities recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability (an exit price) at the measurement date under current market conditions. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance. Fair Value Hierarchy Accounting guidance on fair value measurements requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities. The Company did not have any Level 1 assets as of June 30, 2016 or September 30, 2015. Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability. The Company’s Level 2 assets as of June 30, 2016 consisted of money market funds, commercial paper instruments and corporate debt securities. Fair market values for these assets are based on quoted vendor prices and broker pricing where all significant inputs are observable. To ensure the accuracy of quoted vendor prices and broker pricing, the Company performs regular reviews of investment returns to industry benchmarks and sample tests of individual securities to validate quoted vendor prices with other available market data. Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation. Included in Level 3 liabilities as of June 30, 2016 is $13.9 million of noncurrent contingent consideration liabilities related to achievement of revenue and value-creating milestones associated with the Creagh Medical and NorMedix acquisitions. There were no Level 3 instruments as of September 30, 2015. In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. Assets and Liabilities Measured at Fair Value on a Recurring Basis In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2016: (Dollars in thousands) Quoted Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of June 30, 2016 Assets: Cash equivalents $ — $ 26,087 $ — $ 26,087 Available-for-sale debt securities — 9,523 — 9,523 Total assets $ — $ 35,610 $ — $ 35,610 Liabilities: Contingent consideration - noncurrent $ — $ — $ (13,950 ) $ (13,950 ) Total liabilities $ — $ — $ (13,950 ) $ (13,950 ) The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2015: (Dollars in thousands) Quoted Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of September 30, 2015 Assets: Cash equivalents $ — $ 53,591 $ — $ 53,591 Total assets $ — $ 53,591 $ — $ 53,591 Included in Level 3 fair value measurements as of June 30, 2016 was a $13.9 million noncurrent contingent consideration liability related to achievement of revenue and value-creating milestones associated with the Creagh Medical and NorMedix acquisitions. The following table summarizes the changes in the noncurrent contingent consideration liability for the three and nine month periods ended June 30, 2016: (Dollars in thousands) Current and noncurrent contingent consideration liability as of September 30, 2015 $ — Additions 9,064 Fair value adjustments — Settlements — Interest accretion 109 Foreign currency translation loss 135 Current and noncurrent contingent consideration liability as of December 31, 2015 9,308 Additions 3,517 Fair value adjustments — Settlements — Interest accretion 392 Foreign currency translation loss 429 Current and noncurrent contingent consideration liability as of March 31, 2016 13,646 Additions — Fair value adjustments 70 Settlements — Interest accretion 485 Foreign currency translation gain (251 ) Current and noncurrent contingent consideration liability as of June 30, 2016 $ 13,950 Valuation Techniques The valuation techniques used to measure the fair value of assets are as follows: Cash equivalents — These assets are classified as Level 2 and are carried at historical cost, which is a reasonable estimate of fair value because of the relatively short time between origination of the instrument and its expected realization. Available-for-sale debt securities — These assets are classified as Level 2 and includes corporate debt securities. These securities ae valued based on quoted vendor prices in active markets underlying the securities. Contingent consideration — The contingent consideration liabilities were determined based on discounted cash flow analyses that included revenue estimates, probability of strategic milestone achievement and a discount rate, which are considered significant unobservable inputs as of the acquisition date and June 30, 2016. For the revenue based milestones, the Company discounted forecasted revenue by 14.1% to 22.8%, which represents the Company’s weighted average cost of capital for each transaction, adjusted for the short-term nature of the cash flows. The resulting present value of revenue was used as an input into an option pricing approach, which also considered the Company’s risk of non-payment of the revenue-based milestones. Non-revenue milestones are assumed to have a 75% to 100% probability of achievement and related payments were discounted using the Company’s estimated cost of debt, or 5.6% to 6.7%. To the extent that these assumptions were to change, the fair value of the contingent consideration liabilities could change significantly. Included in the condensed consolidated statement of income for the third quarter and first nine months ended June 30, 2016 is $0.5 million and $1.1 million, respectively, of expense related to the accretion of the contingent consideration. The €12 million contingent consideration related to the Creagh Medical acquisition is denominated in Euros and is not hedged. The Company recorded a $0.3 million and $(0.3) million foreign currency exchange gain (loss) in the third quarter and first nine months of fiscal 2016, respectively, related to this contingent consideration.

Investments

Investments	9 Months Ended
	Jun. 30, 2016
Investments Debt And Equity Securities [Abstract]
Investments	5. Investments Investments consist principally of corporate debt securities and are classified as available-for-sale as of June 30, 2016. Available-for-sale securities are reported at fair value with unrealized gains and losses, net of tax, excluded from the condensed consolidated statements of income and reported in the condensed consolidated statements of comprehensive income as well as a separate component of stockholders’ equity in the condensed consolidated balance sheets, except for other-than-temporary impairments, which are reported as a charge to current earnings. A loss would be recognized when there is an other-than-temporary impairment in the fair value of any individual security classified as available-for-sale, with the associated net unrealized loss reclassified out of accumulated other comprehensive income with a corresponding adjustment to other income. This adjustment results in a new cost basis for the investment. Interest earned on debt securities, including amortization of premiums and accretion of discounts, is included in other income. Realized gains and losses from the sales of debt securities, which are included in other income, are determined using the specific identification method. The amortized cost, unrealized holding gains and losses, and fair value of available for sale securities as of June 30, 2016 were as follows: June 30, 2016 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 9,562 $ 1 $ (40 ) $ 9,523 Total $ 9,562 $ 1 $ (40 ) $ 9,523 During the year ended September 30, 2015, the Company liquidated its investment portfolio to support corporate initiatives, as a result the ending balance of available-for-sale investments as of September 30, 2015 was zero. The following table summarizes sales of available-for-sale debt securities: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2016 2015 2016 2015 Proceeds from sales $ — $ 19,071 $ — $ 21,722 Gross realized gains $ — $ 26 $ — $ 26 Gross realized losses $ — $ (65 ) $ — $ (73 )

Inventories

Inventories	9 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventories	6. Inventories Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead, with cost of product sales determined on a first-in, first-out basis. Inventories consisted of the following components: June 30, September 30, (Dollars in thousands) 2016 2015 Raw materials $ 1,630 $ 1,264 Finished products 1,715 1,715 Total $ 3,345 $ 2,979

Other Assets

Other Assets	9 Months Ended
	Jun. 30, 2016
Investments All Other Investments [Abstract]
Other Assets	7. Other Assets Other assets consist principally of the following: June 30, September 30, (Dollars in thousands) 2016 2015 ViaCyte, Inc. $ 479 $ 479 Other noncurrent assets 195 — Other assets, net $ 674 $ 479 The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. The balance of the investment of $0.5 million, which is net of previously recorded other-than-temporary impairments of $4.8 million is accounted for under the cost method and represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities. The carrying value of each cost method investment is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment.

Intangible Assets

Intangible Assets	9 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets	8. Intangible Assets Intangible assets consist principally of acquired patents and technology, customer relationships, licenses and trademarks. In the first nine months of fiscal 2016, the Company acquired 100% of the shares of Creagh Medical and 100% of the shares of NorMedix. The Company acquired and recorded amounts for certain intangible assets in both the Creagh Medical and NorMedix transactions. The Company recorded amortization expense of $0.8 million and $0.2 million for the third quarter ended June 30, 2016 and 2015, respectively. For the nine months ended June 30, 2016 and 2015, the Company recorded amortization expense of $1.9 million and $0.6 million, respectively. Intangible assets consisted of the following: June 30, 2016 (Dollars in thousands) Weighted Average Original Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 7.8 $ 17,547 $ (5,842 ) $ 11,705 Core technology 8.0 530 (530 ) — Developed technology 11.8 8,701 (417 ) 8,284 Non-compete 5.0 230 (46 ) 184 Patents and other 16.5 2,321 (1,238 ) 1,083 Subtotal 29,329 (8,073 ) 21,256 Unamortized intangible assets: In-process research and development 975 — 975 Trademarks and trade names 658 — 658 Total $ 30,962 $ (8,073 ) $ 22,889 September 30, 2015 (Dollars in thousands) Weighted Average Original Life Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists 9.0 $ 5,132 $ (4,363 ) $ 769 Core technology 8.0 530 (530 ) — Non-compete 5.0 230 (12 ) 218 Patents and other 16.8 2,321 (1,128 ) 1,193 Subtotal 8,213 (6,033 ) 2,180 Unamortized intangible assets: Trademarks 580 — 580 Total $ 8,793 $ (6,033 ) $ 2,760 Based on the intangible assets in service as of June 30, 2016 and the projected completion of in-process research and development assets in fiscal 2017, estimated amortization expense for the remainder of fiscal 2016 and each of the next five fiscal years is as follows: (Dollars in thousands) Remainder of 2016 $ 750 2017 2,570 2018 2,523 2019 2,523 2020 2,348 2021 2,209 Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of completion of the purchase price allocations for Creagh Medical and NorMedix, future acquisitions, impairments, completion of in-process research and development (“IPR&D”) intangible assets, foreign currency fluctuations, changes in amortization periods, or other factors. The Company defines IPR&D as the value of technology acquired for which the related projects have substance and are incomplete. IPR&D acquired in a business acquisition is recognized at fair value and requires the IPR&D to be capitalized as an indefinite-lived intangible asset until completion of the IPR&D project or abandonment. Upon completion of the development project (generally when regulatory approval to market the product is obtained), an impairment assessment is performed prior to amortizing the asset over its estimated useful life. If the IPR&D projects are abandoned, the related IPR&D assets would be written off.

Goodwill

Goodwill	9 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	9. Goodwill Goodwill represents the excess of the cost of an acquired entity over the fair value assigned to the assets purchased and liabilities assumed in connection with a business acquisition. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that the carrying amount of goodwill may be impaired. Goodwill as of June 30, 2016 and September 30, 2015 totaled $26.5 million and $8.0 million, respectively. The $8.0 million of goodwill as of September 30, 2015 is related to the In Vitro Diagnostics reporting unit and represents the gross value from the acquisition of BioFX Laboratories, Inc. (“BioFX”) in 2007. The goodwill was not impaired based on the outcome of the fiscal 2015 annual impairment test, and there have been no events or circumstances that have occurred in the first nine months of fiscal 2016 to indicate that the goodwill has been impaired. In the first quarter of fiscal 2016, the Company purchased Creagh Medical. The purchase price of Creagh Medical exceeded the net acquisition-date amounts of the identifiable assets acquired and the liabilities assumed by $13.6 million. The final valuation of assets acquired and liabilities assumed is expected to be completed as soon as possible, but no later than one year from the acquisition date. In the second quarter of fiscal 2016, the Company purchased NorMedix. The purchase price of NorMedix exceeded the net acquisition-date amounts of the identifiable assets acquired and the liabilities assumed by $4.4 million. The final valuation of assets acquired and liabilities assumed is expected to be completed as soon as possible, but no later than one year from the acquisition date. The change in the carrying amount of goodwill by segment for the nine months ended June 30, 2016 was as follows: (Dollars in thousands) In Vitro Diagnostics Medical Device Total Balance as of September 30, 2015 $ 8,010 $ — $ 8,010 Additions (See Note 3) — 17,988 17,988 Translation adjustment — 546 546 Balance as of June 30, 2016 $ 8,010 $ 18,534 $ 26,544

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	10. Stock-based Compensation The Company has stock-based compensation plans under which it grants stock options, restricted stock awards, performance share awards, restricted stock units and deferred stock units. Accounting guidance requires all share-based payments to be recognized as an operating expense, based on their fair values, over the requisite service period. The Company’s stock-based compensation expenses were allocated to the following expense categories: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2016 2015 2016 2015 Product costs $ 4 $ 5 $ 12 $ 18 Research and development 101 56 220 171 Selling, general and administrative 725 568 2,497 1,652 Total $ 830 $ 629 $ 2,729 $ 1,841 As of June 30, 2016, approximately $4.7 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.2 years. The unrecognized compensation costs above include $1.8 million, remaining to be expensed over the life of the awards, based on payout levels associated with performance share awards that are currently anticipated to be fully expensed because the performance conditions are expected to exceed minimum threshold levels. Stock Option Awards The Company uses the Black-Scholes option pricing model to determine the weighted average grant date fair value of stock options granted. The weighted average per share fair values of stock options granted during the three months ended June 30, 2016 and 2015 were $6.49 and $8.85, respectively. The weighted average per share fair values of stock options granted during the nine months ended June 30, 2016 and 2015 were $6.85 and $7.25, respectively. The assumptions used as inputs in the model were as follows: Three Months Ended Nine Months Ended June 30, June 30, 2016 2015 2016 2015 Risk-free interest rates 1.3 % 1.2 % 1.9 % 1.4 % Expected life (years) 4.7 4.4 4.6 4.5 Expected volatility 35.2 % 38.5 % 36.8 % 43.2 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 % The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award. The expected life of options granted was determined based on the Company’s experience. Expected volatility was based on the Company’s stock price movement over a period approximating the expected term. Based on management’s judgment, dividend yields were expected to be 0.0% for the expected life of the options. The Company also estimates forfeitures of options granted, which were based on historical experience. Non-qualified stock options are granted at fair market value on the date of grant. Non-qualified stock options expire in seven to ten years or upon termination of employment or service as a Board member. With respect to members of our Board, non-qualified stock options generally become exercisable on a pro-rata basis within the one-year period following the date of grant. With respect to our employees, non-qualified stock options generally become exercisable with respect to 25% of the shares on each of the first four anniversaries following the grant date. The total pre-tax intrinsic value of options exercised during the three and nine months ended June 30, 2016 was $0.4 million and $1.7 million, respectively. Restricted Stock Awards The Company has entered into restricted stock agreements with certain key employees, covering the issuance of common stock (“Restricted Stock”). Under accounting guidance, these shares are considered to be non-vested shares. The Restricted Stock is released to the key employees if they are employed by the Company at the end of the vesting period. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation expense table includes Restricted Stock expenses recognized related to these awards, which totaled less than $0.1 million and $0.1 million in each of the three months ended June 30, 2016 and 2015, respectively. in each of the nine months ended June 30, 2016 and 2015, respectively. Performance Share Awards The Company has entered into performance share agreements with certain key employees and executives, covering the issuance of common stock (“Performance Shares”). Performance Shares vest upon the achievement of all or a portion of certain performance objectives (which may include financial or project objectives), which must be achieved during the performance period. The Organization and Compensation Committee of the Board of Directors (the “Committee”) approves the performance objectives used for our executive compensation programs, which objectives were cumulative earnings per share and cumulative revenue for the three-year performance periods for fiscal 2014 (2014 – 2016) and are cumulative revenue and cumulative earnings before interest, income taxes, depreciation and amortization (“EBITDA”) for fiscal year 2015 (2015 – 2017) and fiscal 2016 (2016 – 2018). Assuming that the minimum performance level is attained, the number of shares that may actually vest will vary based on performance from 20% (minimum) to 200% (maximum) of the target number of shares. Shares will be issued to participants as soon as practicable following the end of the performance periods subject to Committee approval and verification of results. The fiscal 2013 awards were finalized in the three months ended December 31, 2015 and resulted in the issuance of 42,458 shares (maximum was 85,506 shares) based on the performance objectives and actual results. The compensation cost related to the number of shares to be granted under each performance period is fixed on the grant date. Compensation expense was recognized in each period based on management’s best estimate of the achievement level of actual and forecasted results, as appropriate, compared with the specified performance objectives for Performance Shares. For the three and nine months ended June 30, 2016, the Company recognized expense of $0.3 million and $1.3 million, respectively. For the three and nine months ended June 30, 2015, the Company recognized expense of $0.2 million and $0.5 million, respectively. The stock-based compensation expense table includes the Performance Shares expense. The fair values of the Performance Shares, at target, were $1.3 million, $0.9 million and $0.9 million in each fiscal year for grants awarded in fiscal 2016, 2015 and 2014, respectively. The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows: Performance Period Minimum Shares Target Shares Maximum Fiscal 2014 – 2016 7,861 39,303 78,606 Fiscal 2015 – 2017 8,440 42,199 84,398 Fiscal 2016 – 2018 13,268 66,338 132,676 Employee Stock Purchase Plan Under the 1999 Employee Stock Purchase Plan (“Stock Purchase Plan”), the Company is authorized to issue up to 400,000 shares of common stock. All full-time and part-time U.S. employees can choose to have up to 10% of their annual compensation withheld, with a limit of $25,000, to purchase the Company’s common stock at purchase prices defined within the provisions of the Stock Purchase Plan. As of June 30, 2016 and 2015, there was $0.1 million of employee contributions included in accrued liabilities in the condensed consolidated balance sheets. Stock compensation expense recognized related to the Stock Purchase Plan for the three and nine months ended June 30, 2016 and 2015 totaled $0.1 million or less in each period. The stock-based compensation table includes the Stock Purchase Plan expenses. Restricted Stock and Deferred Stock Units In the nine months ended June 30, 2016, the Company awarded 18,877 restricted stock units (“RSUs”). The Company has awarded a total of 23,736 RSUs in fiscal 2015 and 2014 under the 2009 Equity Incentive Plan to non-employee directors with forfeiture of 3,068 RSUs in fiscal 2015. RSU awards are not considered issued or outstanding common stock of the Company until they vest. The estimated fair value of the RSU awards was calculated based on the closing market price of Surmodics’ common stock on the date of grant. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation table includes RSU expenses recognized related to these awards, which totaled less than $0.1 million and $0.1 million for the three months and nine months ended June 30, 2016, respectively, and less than $0.1 million and $0.2 million during the three months and nine months ended June 30, 2015, respectively. Directors can also elect to receive their annual fees for services to the Board in deferred stock units (“DSUs”). Certain directors elected this option beginning on January 1, 2013 with deferral elections made annually, which has resulted in 2,134 and 6,646 units issued with a total fair value of less than $0.1 million and $0.1 million in the three months and nine months ended June 30, 2016, respectively, and 1,547 and 4,433 DSUs issued with a total value of less than $0.1 million in the three months and nine months ended June 30, 2015, respectively. These DSUs are fully vested. Stock-based compensation expense related to DSU awards totaled $0.1 million and $0.1 million during the third quarter and nine months ended June 30, 2016, respectively and less than $0.1 million in both the three months and nine months ended June 30, 2015, respectively.

Revolving Credit Facility

Revolving Credit Facility	9 Months Ended
	Jun. 30, 2016
Text Block [Abstract]
Revolving Credit Facility	11. Revolving Credit Facility On November 4, 2013, the Company entered into a three-year $20.0 million secured revolving credit facility. The Company’s obligations under the credit facility are secured by substantially all of its and its subsidiaries’ assets, other than intellectual property and real estate. Borrowings under the credit facility, if any, will bear interest at a benchmark rate plus a margin ranging from 1.375% to 2.00% based on the Company’s leverage ratio. A facility fee is payable on unused commitments at a rate of 0.20% per annum. On November 5, 2014, the credit facility was amended and modified to increase the size of stock repurchases that may be effected by the Company up to $30.0 million without the consent of the lender. During the year ended September 30, 2015, the Company repurchased $20.0 million of common stock. On November 20, 2015, the credit facility was further amended and modified to replenish the size of stock repurchases that may be effected by the Company to up to $30.0 million without the consent of the lender. On March 4, 2016 the credit facility was further amended to consider the Company’s foreign subsidiaries in the credit agreement. In connection with the credit facility, the Company is required to maintain financial covenants related to a maximum leverage ratio and a minimum EBITDA amount and to comply with nonfinancial covenants. As of June 30, 2016, the Company has no debt outstanding and was in compliance with all financial covenants.

Net Income Per Share Data

Net Income Per Share Data	9 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Net Income Per Share Data	12. Net Income Per Share Data Basic net income per common share is calculated by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s potentially dilutive common shares are those that result from dilutive common stock options, non-vested stock relating to restricted stock awards, restricted stock units, deferred stock units and performance shares. The following table sets forth the denominator for the computation of basic and diluted net income per share: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2016 2015 2016 2015 Net income available to common shareholders $ 4,003 $ 3,924 $ 7,341 $ 10,590 Basic weighted average shares outstanding 12,995 13,002 12,969 13,057 Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares 289 277 234 267 Diluted weighted average shares outstanding 13,284 13,279 13,203 13,324 The calculation of weighted average diluted shares outstanding excludes outstanding stock options associated with the right to purchase 0.3 million shares of common stock for each of the three months ended June 30, 2016 and 2015, respectively, and 0.2 million and 0.3 million for the nine months ended June 30, 2016 and June 30, 2015, respectively, as their inclusion would have had an antidilutive effect on diluted net income per share. On November 5, 2014, the Company’s Board of Directors authorized it to repurchase up to $30.0 million of the Company’s outstanding common stock in open-market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, tender offers or by any combination of such methods. The authorization has no fixed expiration date. The Company used $20.0 million of this authorization for the share repurchase discussed below. On November 11, 2014, the Company entered into an accelerated share repurchase (“ASR”) program with Wells Fargo Bank, National Association. In connection with this agreement, the Company made a $20.0 million payment to the bank and immediately received an initial delivery of 758,143 shares of its common stock with a fair value of $16.0 million as of the purchase date. Effective as of the date of the initial share purchase, the transaction was accounted for as a share retirement, resulting in a reduction of common stock of less than $0.1 million, additional paid-in capital of $2.5 million and retained earnings of $13.5 million. The remaining $4.0 million of the Company’s payment was also reported as a reduction in retained earnings. The specific number of shares that the Company ultimately purchased under the ASR agreement was based on the volume weighted average price (“VWAP”) of the Company’s common stock during the purchase period, less an agreed upon discount. In the aggregate, the Company purchased 847,864 shares under the ASR program for an average price of $23.59 per share. Based on the facts associated with the agreement, the forward contract was indexed to the Company’s common stock and met the U.S. GAAP requirements to be classified as permanent equity as of July 8, 2015, the date the ASR program was completed. On November 6, 2015, the Company’s Board of Directors authorized the repurchase of up to $20.0 million of the Company’s outstanding common stock in addition to the $10.0 million authorization which remains available from the November 5, 2014 authorization.

Income Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes For interim income tax reporting, we are required to estimate our annual effective tax rate and apply it to year-to-date pretax income excluding unusual or infrequently occurring discrete items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company recorded income tax provisions of $2.9 million and $1.9 million for the three months ended June 30, The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate as of June 30, The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. U.S. income tax returns for years prior to fiscal 2012 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2005.

Amounts Reclassified Out of Acc

Amounts Reclassified Out of Accumulated Other Comprehensive Income	9 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Amounts Reclassified Out of Accumulated Other Comprehensive Income	14. Amounts Reclassified Out of Accumulated Other Comprehensive Income Amounts reclassified out of accumulated other comprehensive income (“AOCI”) was $0.3 million on a pre-tax basis for the nine months ended June 30, 2015. There were no amounts reclassified out of AOCI for the three and nine months ended June 30, 2016. For the three months and nine months ended June 30, 2015, the amounts reclassified out of AOCI were associated with unrealized gains or losses on available-for-sale securities that were realized on the sale of the securities and were presented in other income, net in the condensed consolidated statements of income.

Reportable Segment Information

Reportable Segment Information	9 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Reportable Segment Information	15. Reportable Segment Information The accounting standards for reporting information about operating segments define operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. For financial accounting and reporting purposes, the Company reports its results for the two reportable segments as follows: (1) the Medical Device unit, which is comprised of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing; as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings. During the first nine months of fiscal 2016, the Company acquired Creagh Medical and NorMedix, which are included in the Medical Device segment. The table below presents segment revenue, operating income and depreciation and amortization, as follows: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2016 2015 2016 2015 Revenue: Medical Device $ 15,654 $ 11,629 $ 39,500 $ 32,827 In Vitro Diagnostics 4,318 4,285 13,712 11,708 Total revenue $ 19,972 $ 15,914 $ 53,212 $ 44,535 Operating income: Medical Device $ 6,673 $ 6,295 $ 12,825 $ 16,507 In Vitro Diagnostics 1,673 1,191 5,298 3,220 Total segment operating income 8,346 7,486 18,123 19,727 Corporate (1,749 ) (1,629 ) (5,347 ) (4,903 ) Total operating income $ 6,597 $ 5,857 $ 12,776 $ 14,824 Depreciation and amortization: Medical Device $ 982 $ 288 $ 2,440 $ 852 In Vitro Diagnostics 222 215 647 645 Corporate 202 191 616 586 Total depreciation and amortization $ 1,406 $ 694 $ 3,703 $ 2,083 The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments. Asset information by operating segment is not presented because the Company does not provide its chief operating decision maker assets by operating segment, as the data is not readily available.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	16. Commitments and Contingencies Litigation. From time to time, the Company has been, and may become, involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which if granted, could require significant expenditures or result in lost revenue. The Company records a liability in the condensed consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. InnoRx, Inc. In January 2005, the Company entered into a merger agreement whereby the Company acquired all of the assets of InnoRx, Inc. (“InnoRx”), an early stage company developing drug delivery devices and therapies for the ophthalmology market. The Company will be required to issue up to approximately 480,059 additional shares of its common stock to the stockholders of InnoRx upon the successful completion of the remaining development and commercial milestones involving InnoRx technology acquired in the transaction. The Company has not recorded any accrual for this contingency as of June 30, 2016 as the milestones have not been achieved and the probability of achievement is remote. InnoCore Technologies BV . In March 2006, the Company entered into a license agreement whereby Surmodics obtained an exclusive license to a drug delivery coating for licensed products within the vascular field which included peripheral, coronary and neurovascular biodurable stent products. The license requires an annual minimum payment of 200,000 euros (equivalent to $221,660 using a euro to US dollar exchange rate of 1.1083 to the Euro as of June 30, 2016) until the last patent expires which is currently estimated to be September 2027. The total minimum future payments associated with this license are approximately $2.7 million. The license is currently utilized by one of the Company’s drug delivery customers.

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Jun. 30, 2016
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Summary of Purchase Price	The purchase price of Creagh Medical consisted of the following: (Dollars in thousands) Cash paid $ 18,417 Debt assumed 793 Contingent consideration 9,064 Total purchase price 28,274 Less cash and cash equivalents acquired (251 ) Total purchase price, net of cash acquired $ 28,023
Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed	The following table summarizes the preliminary allocation of the purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the Creagh Medical acquisition: Fair Value (Dollars Estimated (In Current assets $ 708 N/A Property and equipment 634 1.0-10.0 Trade name 75 N/A Developed technology 1,787 7.0 In-process research and development 942 N/A Customer relationships 11,119 7.0-10.0 Other noncurrent assets 81 N/A Current liabilities (923 ) N/A Deferred tax liabilities (9 ) N/A Net assets acquired 14,414 Goodwill 13,609 N/A Total purchase price, net of cash acquired $ 28,023
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Summary of Purchase Price	The purchase price of NorMedix consisted of the following: (Dollars in thousands) Cash paid $ 6,905 Contingent consideration 3,740 Total purchase price 10,645 Less cash and cash equivalents acquired (17 ) Total purchase price, net of cash acquired $ 10,628
Schedule of Purchase Price to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the preliminary purchase price to the fair values assigned to the assets acquired and the liabilities assumed at the date of the NorMedix acquisition: Fair Value (Dollars Estimated Useful Life (In years) Net current assets $ 196 N/A Property and equipment 76 N/A Developed technology 6,850 10.0-14.0 Customer relationships 900 4.0 Deferred tax asset 812 N/A Other noncurrent asset 12 N/A Deferred tax liabilities (2,597 ) N/A Net assets acquired 6,249 Goodwill 4,379 N/A Total purchase price, net of cash acquired $ 10,628
Creagh Medical and NorMedix [Member]
Business Acquisition [Line Items]
Schedule of Pro Forma Financial Information	Three Months Ended Nine Months Ended June 30, June 30, 2015 2016 2015 (In thousands, except per share data) (Unaudited) (Unaudited) Revenue $ 16,858 $ 54,262 $ 46,922 Net income $ 1,232 $ 6,857 $ 2,347 Per share amounts: Basic net income per share $ 0.09 $ 0.53 $ 0.18 Diluted net income per share $ 0.09 $ 0.52 $ 0.18

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2016: (Dollars in thousands) Quoted Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of June 30, 2016 Assets: Cash equivalents $ — $ 26,087 $ — $ 26,087 Available-for-sale debt securities — 9,523 — 9,523 Total assets $ — $ 35,610 $ — $ 35,610 Liabilities: Contingent consideration - noncurrent $ — $ — $ (13,950 ) $ (13,950 ) Total liabilities $ — $ — $ (13,950 ) $ (13,950 ) The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2015: (Dollars in thousands) Quoted Active Markets for Identical Instruments (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Fair Value as of September 30, 2015 Assets: Cash equivalents $ — $ 53,591 $ — $ 53,591 Total assets $ — $ 53,591 $ — $ 53,591
Schedule of Contingent Consideration Liability	The following table summarizes the changes in the noncurrent contingent consideration liability for the three and nine month periods ended June 30, 2016: (Dollars in thousands) Current and noncurrent contingent consideration liability as of September 30, 2015 $ — Additions 9,064 Fair value adjustments — Settlements — Interest accretion 109 Foreign currency translation loss 135 Current and noncurrent contingent consideration liability as of December 31, 2015 9,308 Additions 3,517 Fair value adjustments — Settlements — Interest accretion 392 Foreign currency translation loss 429 Current and noncurrent contingent consideration liability as of March 31, 2016 13,646 Additions — Fair value adjustments 70 Settlements — Interest accretion 485 Foreign currency translation gain (251 ) Current and noncurrent contingent consideration liability as of June 30, 2016 $ 13,950

Investments (Tables)

Investments (Tables)	9 Months Ended
	Jun. 30, 2016
Investments Debt And Equity Securities [Abstract]
Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities	The amortized cost, unrealized holding gains and losses, and fair value of available for sale securities as of June 30, 2016 were as follows: June 30, 2016 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 9,562 $ 1 $ (40 ) $ 9,523 Total $ 9,562 $ 1 $ (40 ) $ 9,523
Sales of Available-for-Sale Debt Securities	The following table summarizes sales of available-for-sale debt securities: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2016 2015 2016 2015 Proceeds from sales $ — $ 19,071 $ — $ 21,722 Gross realized gains $ — $ 26 $ — $ 26 Gross realized losses $ — $ (65 ) $ — $ (73 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Components of Inventories	Inventories consisted of the following components: June 30, September 30, (Dollars in thousands) 2016 2015 Raw materials $ 1,630 $ 1,264 Finished products 1,715 1,715 Total $ 3,345 $ 2,979

Other Assets (Tables)

Other Assets (Tables)	9 Months Ended
	Jun. 30, 2016
Investments All Other Investments [Abstract]
Summary of Other Assets	Other assets consist principally of the following: June 30, September 30, (Dollars in thousands) 2016 2015 ViaCyte, Inc. $ 479 $ 479 Other noncurrent assets 195 — Other assets, net $ 674 $ 479

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: June 30, 2016 (Dollars in thousands) Weighted Average Original Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists and relationships 7.8 $ 17,547 $ (5,842 ) $ 11,705 Core technology 8.0 530 (530 ) — Developed technology 11.8 8,701 (417 ) 8,284 Non-compete 5.0 230 (46 ) 184 Patents and other 16.5 2,321 (1,238 ) 1,083 Subtotal 29,329 (8,073 ) 21,256 Unamortized intangible assets: In-process research and development 975 — 975 Trademarks and trade names 658 — 658 Total $ 30,962 $ (8,073 ) $ 22,889 September 30, 2015 (Dollars in thousands) Weighted Average Original Life Gross Carrying Amount Accumulated Amortization Net Definite-lived intangible assets: Customer lists 9.0 $ 5,132 $ (4,363 ) $ 769 Core technology 8.0 530 (530 ) — Non-compete 5.0 230 (12 ) 218 Patents and other 16.8 2,321 (1,128 ) 1,193 Subtotal 8,213 (6,033 ) 2,180 Unamortized intangible assets: Trademarks 580 — 580 Total $ 8,793 $ (6,033 ) $ 2,760
Estimated Amortization Expense	Based on the intangible assets in service as of June 30, 2016 and the projected completion of in-process research and development assets in fiscal 2017, estimated amortization expense for the remainder of fiscal 2016 and each of the next five fiscal years is as follows: (Dollars in thousands) Remainder of 2016 $ 750 2017 2,570 2018 2,523 2019 2,523 2020 2,348 2021 2,209

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Jun. 30, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule Of Carrying Amount Of Goodwill By Segment	The change in the carrying amount of goodwill by segment for the nine months ended June 30, 2016 was as follows: (Dollars in thousands) In Vitro Diagnostics Medical Device Total Balance as of September 30, 2015 $ 8,010 $ — $ 8,010 Additions (See Note 3) — 17,988 17,988 Translation adjustment — 546 546 Balance as of June 30, 2016 $ 8,010 $ 18,534 $ 26,544

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation Expenses	The Company’s stock-based compensation expenses were allocated to the following expense categories: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2016 2015 2016 2015 Product costs $ 4 $ 5 $ 12 $ 18 Research and development 101 56 220 171 Selling, general and administrative 725 568 2,497 1,652 Total $ 830 $ 629 $ 2,729 $ 1,841
Assumptions Used in Stock Option Plans	The assumptions used as inputs in the model were as follows: Three Months Ended Nine Months Ended June 30, June 30, 2016 2015 2016 2015 Risk-free interest rates 1.3 % 1.2 % 1.9 % 1.4 % Expected life (years) 4.7 4.4 4.6 4.5 Expected volatility 35.2 % 38.5 % 36.8 % 43.2 % Dividend yield 0.0 % 0.0 % 0.0 % 0.0 %
Schedule of Fair Value at the Date of Grant	The aggregate number of shares that could be awarded to our executives if the minimum, target and maximum performance goals are met, based on the fair value at the date of grant is as follows: Performance Period Minimum Shares Target Shares Maximum Fiscal 2014 – 2016 7,861 39,303 78,606 Fiscal 2015 – 2017 8,440 42,199 84,398 Fiscal 2016 – 2018 13,268 66,338 132,676

Net Income Per Share Data (Tabl

Net Income Per Share Data (Tables)	9 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Denominator for Computation of Basic and Diluted Net Income Per Share	The following table sets forth the denominator for the computation of basic and diluted net income per share: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2016 2015 2016 2015 Net income available to common shareholders $ 4,003 $ 3,924 $ 7,341 $ 10,590 Basic weighted average shares outstanding 12,995 13,002 12,969 13,057 Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares 289 277 234 267 Diluted weighted average shares outstanding 13,284 13,279 13,203 13,324

Reportable Segment Information

Reportable Segment Information (Tables)	9 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Segment Revenue, Operating Income and Depreciation and Amortization	The table below presents segment revenue, operating income and depreciation and amortization, as follows: Three Months Ended Nine Months Ended June 30, June 30, (Dollars in thousands) 2016 2015 2016 2015 Revenue: Medical Device $ 15,654 $ 11,629 $ 39,500 $ 32,827 In Vitro Diagnostics 4,318 4,285 13,712 11,708 Total revenue $ 19,972 $ 15,914 $ 53,212 $ 44,535 Operating income: Medical Device $ 6,673 $ 6,295 $ 12,825 $ 16,507 In Vitro Diagnostics 1,673 1,191 5,298 3,220 Total segment operating income 8,346 7,486 18,123 19,727 Corporate (1,749 ) (1,629 ) (5,347 ) (4,903 ) Total operating income $ 6,597 $ 5,857 $ 12,776 $ 14,824 Depreciation and amortization: Medical Device $ 982 $ 288 $ 2,440 $ 852 In Vitro Diagnostics 222 215 647 645 Corporate 202 191 616 586 Total depreciation and amortization $ 1,406 $ 694 $ 3,703 $ 2,083

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 29, 2016	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2015
Basis Of Presentation [Line Items]
Royalty and license fee	$ 2,900	$ 10,556	$ 7,908		$ 25,207	$ 22,566
Royalty payment period					2009 through fiscal 2016
Payables to customers		1,741			$ 1,741		$ 63
Out of Period Royalty Adjustment [Member]
Basis Of Presentation [Line Items]
Royalty and license fee					1,100
Prior Year Period Royalty Adjustment [Member]
Basis Of Presentation [Line Items]
Royalty and license fee				$ 1,000
Settlement Agreement [Member]
Basis Of Presentation [Line Items]
Payables to customers		$ 1,400			$ 1,400

Business Combinations - Additio

Business Combinations - Additional Information (Detail) $ in Thousands, € in Millions	Jan. 08, 2016USD ($)	Nov. 20, 2015USD ($)	Nov. 20, 2015EUR (€)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Nov. 20, 2015EUR (€)
Business Acquisition [Line Items]
Acquisition transaction, integration and other costs				$ 61			$ 3,192
Business acquisition, revenue recognized				19,972		$ 15,914	53,212	$ 44,535
Business acquisition, net loss recognized				4,003		3,924	7,341	10,590
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage		100.00%							100.00%
Payments to acquire business							28,274
Upfront payments		$ 19,300	€ 18				18,417
Contingent milestone payments		12,800							€ 12
Payments for repurchase of securities							800
Repayments of assumed debt					$ 800
Acquisition transaction, integration and other costs							2,700
Creagh Medical Ltd [Member] | Maximum [Member]
Business Acquisition [Line Items]
Payments to acquire business		$ 32,000	€ 30
Acquisition transaction, integration and other costs				100
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Outstanding common shares and voting shares percentage	100.00%
Payments to acquire business	$ 14,000						10,645
Upfront payments	6,900						6,905
Contingent milestone payments	$ 7,000
Acquisition transaction, integration and other costs				$ 0			300
Creagh Medical and NorMedix [Member]
Business Acquisition [Line Items]
Business acquisition, revenue recognized							2,800
Business acquisition, net loss recognized							(2,300)
Creagh Medical and NorMedix [Member] | Pro Forma [Member]
Business Acquisition [Line Items]
Amortization expense on intangible assets						600	400	1,900
Contingent consideration accretion expense						100	300	900
Non-recurring professional fees							3,000
Tax effect impact						$ 100	$ 100	$ 400

Business Combinations - Summary

Business Combinations - Summary of Purchase Price (Detail) $ in Thousands, € in Millions	Jan. 08, 2016USD ($)	Nov. 20, 2015USD ($)	Nov. 20, 2015EUR (€)	Jun. 30, 2016USD ($)	Jun. 30, 2016EUR (€)
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Cash Paid		$ 19,300	€ 18	$ 18,417
Debt assumed				793
Contingent consideration				9,064	€ 12
Payments to acquire business				28,274
Less cash and cash equivalents acquired				(251)
Total purchase price, net of cash acquired				28,023
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Cash Paid	$ 6,900			6,905
Contingent consideration				3,740
Payments to acquire business	$ 14,000			10,645
Less cash and cash equivalents acquired				(17)
Total purchase price, net of cash acquired				$ 10,628

Business Combinations - Summa36

Business Combinations - Summary of Purchase Price Allocation to the Fair Values Assigned to the Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	9 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015
Business Acquisition [Line Items]
Goodwill	$ 26,544			$ 8,010
Developed Technology [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	11 years 9 months 18 days
Creagh Medical Ltd [Member]
Business Acquisition [Line Items]
Current assets	$ 708
Property and equipment	634
Other noncurrent assets	81
Current liabilities	(923)
Deferred tax liabilities	(9)
Net assets acquired	14,414
Goodwill	13,609		$ 13,600
Total purchase price, net of cash acquired	$ 28,023
Creagh Medical Ltd [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	1 year
Creagh Medical Ltd [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 1,787
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] | In-Process Research and Development [Member]
Business Acquisition [Line Items]
Intangible assets	$ 942
Creagh Medical Ltd [Member] | Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 11,119
Creagh Medical Ltd [Member] | Customer Relationship [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	7 years
Creagh Medical Ltd [Member] | Customer Relationship [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
Creagh Medical Ltd [Member] | Trade Name [Member]
Business Acquisition [Line Items]
Intangible assets	$ 75
NorMedix, Inc. [Member]
Business Acquisition [Line Items]
Current assets	196
Property and equipment	76
Deferred tax asset	812
Other noncurrent assets	12
Deferred tax liabilities	(2,597)
Net assets acquired	6,249
Goodwill	4,379	$ 4,400
Total purchase price, net of cash acquired	10,628
NorMedix, Inc. [Member] | Developed Technology [Member]
Business Acquisition [Line Items]
Intangible assets	$ 6,850
NorMedix, Inc. [Member] | Developed Technology [Member] | Minimum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	10 years
NorMedix, Inc. [Member] | Developed Technology [Member] | Maximum [Member]
Business Acquisition [Line Items]
Estimated Useful Life (In years)	14 years
NorMedix, Inc. [Member] | Customer Relationship [Member]
Business Acquisition [Line Items]
Intangible assets	$ 900
Estimated Useful Life (In years)	4 years

Business Combinations - Pro For

Business Combinations - Pro Forma Financial Information (Detail) - Creagh Medical and NorMedix [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Business Acquisition [Line Items]
Revenue	$ 16,858	$ 54,262	$ 46,922
Net income	$ 1,232	$ 6,857	$ 2,347
Per share amounts:
Basic net income per share	$ 0.09	$ 0.53	$ 0.18
Diluted net income per share	$ 0.09	$ 0.52	$ 0.18

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) € in Millions	3 Months Ended	9 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2016EUR (€)	Sep. 30, 2015USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability, noncurrent	$ 13,950,000	$ 13,950,000
Level 3 instruments				$ 0
Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.		75.00%
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of Probability Achievement of Contingent Consideration payment.		100.00%
Contingent Consideration [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Foreign currency exchange gain (loss)	300,000	$ (300,000)
Interest accretion	500,000	$ 1,100,000
Contingent Consideration [Member] | Minimum [Member] | Non Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate		5.60%
Contingent Consideration [Member] | Minimum [Member] | Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate		14.10%
Contingent Consideration [Member] | Maximum [Member] | Non Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate		6.70%
Contingent Consideration [Member] | Maximum [Member] | Revenue Based Milestones [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Inputs, Discount Rate		22.80%
Creagh Medical and NorMedix [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability, noncurrent	13,900,000	$ 13,900,000
Creagh Medical Ltd [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Contingent consideration liability	$ 9,064,000	$ 9,064,000	€ 12

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Member] - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	$ 35,610	$ 53,591
Liabilities measured at fair value	(13,950)
Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	9,523
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	35,610	53,591
Significant Other Observable Inputs (Level 2) [Member] | Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	9,523
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(13,950)
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	26,087	53,591
Cash equivalents [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Assets measured at fair value	26,087	$ 53,591
Contingent consideration - noncurrent [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	(13,950)
Contingent consideration - noncurrent [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Liabilities measured at fair value	$ (13,950)

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Measurement of Contingent Consideration Liability (Detail) - Contingent Consideration [Member] - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Current and noncurrent contingent consideration liability	$ 13,646	$ 9,308
Additions		3,517	$ 9,064
Fair value adjustments	70
Interest accretion	485	392	109
Foreign currency translation loss (gain)	(251)	429	135
Current and noncurrent contingent consideration liability	$ 13,950	$ 13,646	$ 9,308

Investments - Amortized Cost, U

Investments - Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities (Detail) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 9,562,000
Unrealized Gains	1,000
Unrealized Losses	(40,000)
Fair Value	9,523,000	$ 0
Corporate bonds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	9,562,000
Unrealized Gains	1,000
Unrealized Losses	(40,000)
Fair Value	$ 9,523,000

Investments - Additional Inform

Investments - Additional Information (Detail) - USD ($)	Jun. 30, 2016	Sep. 30, 2015
Investments Debt And Equity Securities [Abstract]
Available for sale investment	$ 9,523,000	$ 0

Investments - Sales of Availabl

Investments - Sales of Available-for-Sale Securities (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2015
Investments Debt And Equity Securities [Abstract]
Proceeds from sales	$ 19,071	$ 21,722
Gross realized gains	26	26
Gross realized losses	$ (65)	$ (73)

Inventories - Components of Inv

Inventories - Components of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Sep. 30, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 1,630	$ 1,264
Finished products	1,715	1,715
Total	$ 3,345	$ 2,979

Other Assets - Summary of Other

Other Assets - Summary of Other Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Sep. 30, 2015
Schedule of Investments [Line Items]
Other assets, net	$ 674	$ 479
ViaCyte, Inc. [Member]
Schedule of Investments [Line Items]
Other assets, net	479	$ 479
Other Noncurrent Assets [Member]
Schedule of Investments [Line Items]
Other assets, net	$ 195

Other Assets - Additional Infor

Other Assets - Additional Information (Detail) - ViaCyte, Inc. [Member] $ in Millions	9 Months Ended
	Jun. 30, 2016USD ($)
Schedule of Investments [Line Items]
Equity method investment	$ 5.3
Other than temporary impairment loss on investment	4.8
Cost method of investment	$ 0.5
Maximum [Member]
Schedule of Investments [Line Items]
Company's ownership percentage	1.00%

Intangible Assets - Additional

Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Intangible Assets [Line Items]
Amortization expense	$ 0.8	$ 0.2	$ 1.9	$ 0.6
Creagh Medical [Member]
Intangible Assets [Line Items]
Percentage of shares acquired	100.00%		100.00%
NorMedix [Member]
Intangible Assets [Line Items]
Percentage of shares acquired	100.00%		100.00%

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Jun. 30, 2016	Sep. 30, 2015
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (8,073)	$ (6,033)
Intangible assets, Gross Carrying Amount	30,962	8,793
Intangible assets, Net	$ 22,889	$ 2,760
Customer Lists and Relationships [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	7 years 9 months 18 days
Definite-lived intangible assets, Gross Carrying Amount	$ 17,547
Definite-lived intangible assets, Accumulated Amortization	(5,842)
Definite-lived intangible assets, Net	$ 11,705
Customer Lists [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)		9 years
Definite-lived intangible assets, Gross Carrying Amount		$ 5,132
Definite-lived intangible assets, Accumulated Amortization		(4,363)
Definite-lived intangible assets, Net		$ 769
Core Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years	8 years
Definite-lived intangible assets, Gross Carrying Amount	$ 530	$ 530
Definite-lived intangible assets, Accumulated Amortization	$ (530)	$ (530)
Developed Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	11 years 9 months 18 days
Definite-lived intangible assets, Gross Carrying Amount	$ 8,701
Definite-lived intangible assets, Accumulated Amortization	(417)
Definite-lived intangible assets, Net	$ 8,284
Non-compete [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	5 years	5 years
Definite-lived intangible assets, Gross Carrying Amount	$ 230	$ 230
Definite-lived intangible assets, Accumulated Amortization	(46)	(12)
Definite-lived intangible assets, Net	$ 184	$ 218
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	16 years 6 months	16 years 9 months 18 days
Definite-lived intangible assets, Gross Carrying Amount	$ 2,321	$ 2,321
Definite-lived intangible assets, Accumulated Amortization	(1,238)	(1,128)
Definite-lived intangible assets, Net	1,083	1,193
In-Process Research and Development [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	975
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	29,329	8,213
Definite-lived intangible assets, Accumulated Amortization	(8,073)	(6,033)
Definite-lived intangible assets, Net	21,256	2,180
Trademarks and Trade Names [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 658
Trademarks [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net		$ 580

Intangible Assets - Estimated A

Intangible Assets - Estimated Amortization Expense (Detail) $ in Thousands	Jun. 30, 2016USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Remainder of 2016	$ 750
2,017	2,570
2,018	2,523
2,019	2,523
2,020	2,348
2,021	$ 2,209

Goodwill - Additional Informati

Goodwill - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015
Goodwill [Line Items]
Goodwill	$ 26,544			$ 8,010
Creagh Medical Ltd [Member]
Goodwill [Line Items]
Goodwill	13,609		$ 13,600
NorMedix, Inc. [Member]
Goodwill [Line Items]
Goodwill	4,379	$ 4,400
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Goodwill	$ 8,010			$ 8,010

Goodwill - Schedule Of Carrying

Goodwill - Schedule Of Carrying Amount of Goodwill by Segment (Detail) $ in Thousands	9 Months Ended
	Jun. 30, 2016USD ($)
Goodwill [Line Items]
Balance as of September 30, 2015	$ 8,010
Additions (See Note 3)	17,988
Translation adjustment	546
Balance as of June 30, 2016	26,544
In Vitro Diagnostics [Member]
Goodwill [Line Items]
Balance as of September 30, 2015	8,010
Additions (See Note 3)	0
Translation adjustment	0
Balance as of June 30, 2016	8,010
Medical Device [Member]
Goodwill [Line Items]
Balance as of September 30, 2015	0
Additions (See Note 3)	17,988
Translation adjustment	546
Balance as of June 30, 2016	$ 18,534

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 830	$ 629	$ 2,729	$ 1,841
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	4	5	12	18
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	101	56	220	171
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 725	$ 568	$ 2,497	$ 1,652

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs related to non-vested awards	$ 4,700,000			$ 4,700,000
Weighted average period for recognition of compensation costs related to non-vested awards				2 years 2 months 12 days
Performance share awards fully expensed	$ 1,800,000			$ 1,800,000
Weighted average per share fair value of stock options	$ 6.49		$ 8.85	$ 6.85	$ 7.25
Dividend yield	0.00%		0.00%	0.00%	0.00%
Vesting period							3 years	3 years
Total pre-tax intrinsic value of options exercised	$ 400,000		$ 300,000	$ 1,700,000	$ 1,700,000
Restricted stock expense				200,000	200,000
Stock compensation expenses recognized	830,000		629,000	$ 2,729,000	1,841,000
Fiscal 2014 (2014 - 2016) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year				2,014
Performance period end year				2,016
Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year				2,015
Performance period end year				2,017
Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year				2,016
Performance period end year				2,018
Scenario Forecast
Stock-Based Compensation Activity [Line Items]
Vesting period						3 years
Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Restricted stock expense	100,000		100,000
Nonqualified Stock Options [Member] | Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period				4 years
Nonqualified Stock Options [Member] | Minimum [Member] | Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service				7 years
Nonqualified Stock Options [Member] | Maximum [Member] | Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service				10 years
Performance Shares [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	300,000		200,000	$ 1,300,000	500,000
Issuance of shares		42,458
Performance Shares [Member] | Fiscal 2014 (2014 - 2016) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded								$ 900,000
Performance Shares [Member] | Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded							$ 900,000
Performance Shares [Member] | Scenario Forecast | Fiscal 2016 (2016 - 2018) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded						$ 1,300,000
Performance Shares [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Issuance of shares		85,506
1999 Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Annual compensation withheld, maximum limit				25,000
Employee contributions	100,000		100,000	100,000	100,000
1999 Employee Stock Purchase Plan [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000		100,000	$ 100,000	100,000
Common stock authorized, shares	400,000			400,000
Annual compensation withheld				10.00%
Restricted Stock Units (RSUs) [Member] | 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized				$ 100,000	$ 200,000
Number of stock units awarded				18,877			23,736	23,736
Number of stock units forfeited							3,068
Restricted Stock Units (RSUs) [Member] | Maximum [Member] | 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000		$ 100,000
Deferred Stock Units [Member] | 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized	$ 100,000			$ 100,000
Deferred Stock Units [Member] | 2009 Equity Incentive Plan [Member] | Director [Member]
Stock-Based Compensation Activity [Line Items]
Number of stock units awarded	2,134		1,547	6,646	4,433
Deferred Stock Units [Member] | Maximum [Member] | 2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized			$ 100,000		$ 100,000
Deferred Stock Units [Member] | Maximum [Member] | 2009 Equity Incentive Plan [Member] | Director [Member]
Stock-Based Compensation Activity [Line Items]
Number of deferred stock units issued fair value	$ 100,000		$ 100,000	$ 100,000	$ 100,000
Vesting Anniversary [Member] | Nonqualified Stock Options [Member] | Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage				25.00%
Performance Level [Member] | Minimum [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage				20.00%
Performance Level [Member] | Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Performance share awards, estimated vesting percentage				200.00%

Stock-based Compensation - Assu

Stock-based Compensation - Assumptions Used in Stock Option Plans (Detail)	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rates	1.30%	1.20%	1.90%	1.40%
Expected life (years)	4 years 8 months 12 days	4 years 4 months 24 days	4 years 7 months 6 days	4 years 6 months
Expected volatility	35.20%	38.50%	36.80%	43.20%
Dividend yield	0.00%	0.00%	0.00%	0.00%

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Fair Value at the Date of Grant (Detail)	9 Months Ended
	Jun. 30, 2016shares
Fiscal 2014 (2014 - 2016) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	7,861
Target Shares	39,303
Maximum Shares	78,606
Fiscal 2015 (2015 - 2017) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	8,440
Target Shares	42,199
Maximum Shares	84,398
Fiscal 2016 (2016 - 2018) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	13,268
Target Shares	66,338
Maximum Shares	132,676

Revolving Credit Facility - Add

Revolving Credit Facility - Additional Information (Detail) - Revolving Credit Facility [Member] - USD ($)	Nov. 04, 2013	Sep. 30, 2015	Jun. 30, 2016	Nov. 20, 2015	Nov. 05, 2014
Line Of Credit Facility [Line Items]
Credit facility initiation date	Nov. 4, 2013
Revolving credit facility amount	$ 20,000,000
Credit facility fee percentage	0.20%
Line of Credit Facility, Expiration Period	3 years
Common stock repurchased, Value		$ 20,000,000
Debt outstanding			$ 0
Stock Repurchase Plan [Member]
Line Of Credit Facility [Line Items]
Revolving credit facility amount				$ 30,000,000	$ 30,000,000
Minimum [Member]
Line Of Credit Facility [Line Items]
Credit facility interest rate	1.375%
Maximum [Member]
Line Of Credit Facility [Line Items]
Credit facility interest rate	2.00%

Net Income Per Share Data - Den

Net Income Per Share Data - Denominator for Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Earnings Per Share [Abstract]
Net income available to common shareholders	$ 4,003	$ 3,924	$ 7,341	$ 10,590
Basic weighted average shares outstanding	12,995	13,002	12,969	13,057
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units, deferred stock units and performance shares	289	277	234	267
Diluted weighted average shares outstanding	13,284	13,279	13,203	13,324

Net Income Per Share Data - Add

Net Income Per Share Data - Additional Information (Detail) - USD ($)	Nov. 11, 2014	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Nov. 06, 2015	Nov. 05, 2014
Earnings Loss Per Share [Line Items]
Weighted average diluted shares outstanding excluded outstanding stock options		300,000	300,000	200,000	300,000
Common stock outstanding in additional						$ 10,000,000
Accelerated Share Repurchase Program [Member]
Earnings Loss Per Share [Line Items]
Maximum payments for repurchase of common stock						$ 20,000,000	$ 30,000,000
Fair value of common stock	$ 16,000,000
Reduction in common stock	100,000
Reduction in additional paid-in capital	2,500,000
Reduction in retained earnings	13,500,000
Initial payment to bank reported as reduction in retained earnings	$ 4,000,000
Common stock repurchased, Shares	847,864
Accelerate share repurchase program, price per share	$ 23.59
Accelerated Share Repurchase Program [Member] | Investment Bank [Member]
Earnings Loss Per Share [Line Items]
Fair value of common stock	$ 20,000,000
Common stock repurchased, Shares	758,143

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income tax provisions	$ 2,857	$ 1,929	$ 5,507	$ 4,879
Effective tax rates	41.60%	33.00%	42.90%	31.50%
U.S. federal statutory tax rate	35.00%		35.00%
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate	$ 1,000		$ 1,000		$ 900

Amounts Reclassified Out of A60

Amounts Reclassified Out of Accumulated Other Comprehensive Income - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015
Accumulated Other Comprehensive Income Loss [Line Items]
Amounts reclassified out of AOCI	$ 0	$ 0
Maximum [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Amounts reclassified out of AOCI pre-tax basis			$ 300,000

Reportable Segment Informatio61

Reportable Segment Information - Additional Information (Detail)	9 Months Ended
	Jun. 30, 2016Segment
Segment Reporting [Abstract]
Number of operating segments	2

Reportable Segment Informatio62

Reportable Segment Information - Segment Revenue, Operating Income and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
Total revenue	$ 19,972	$ 15,914	$ 53,212	$ 44,535
Operating income	6,597	5,857	12,776	14,824
Depreciation and amortization	1,406	694	3,703	2,083
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income	8,346	7,486	18,123	19,727
Operating Segments [Member] | Medical Device [Member]
Segment Reporting Information [Line Items]
Total revenue	15,654	11,629	39,500	32,827
Operating income	6,673	6,295	12,825	16,507
Depreciation and amortization	982	288	2,440	852
Operating Segments [Member] | In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Total revenue	4,318	4,285	13,712	11,708
Operating income	1,673	1,191	5,298	3,220
Depreciation and amortization	222	215	647	645
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income	(1,749)	(1,629)	(5,347)	(4,903)
Depreciation and amortization	$ 202	$ 191	$ 616	$ 586

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - 9 months ended Jun. 30, 2016	USD ($)€ / $shares	EUR (€)shares
Commitments And Contingencies [Line Items]
Additional shares of common stock to stockholders | shares	480,059	480,059
Annual minimum payments for licenses	$ 221,660	€ 200,000
Exchange rate relating to license payment | € / $	1.1083
License agreement commencement date	2006-03	2006-03
Future minimum payments associated with license | $	$ 2,700,000
Patents [Member]
Commitments And Contingencies [Line Items]
Patent expiry date	2027-09	2027-09